Temozolomide in second-line treatment after prior nitrosurea-based chemotherapy in glioblastoma multiforme: Experience from a Portuguese institution

International Journal of Clinical Pharmacology Research

Volumn 22, Issue 1, 2002, Pages 19-22

  Teixeira, M M ^a   Garcia, I ^a   Portela, I ^a   Cernuda, M ^a   Oliveira, C ^a   Albano, J ^a   Lima, L ^a  

^a Instituto Portugues de Oncologia Francisco Gentil Centro Regional de Oncologia de Coimbra SA   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; CARMUSTINE; NITROSOUREA DERIVATIVE; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CLINICAL ARTICLE; GLIOBLASTOMA; HUMAN; KAPLAN MEIER METHOD; PORTUGAL; RECURRENT CANCER; SURVIVAL RATE; SURVIVAL TIME;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; DACARBAZINE; DRUG ADMINISTRATION SCHEDULE; GLIOBLASTOMA; HUMANS; MIDDLE AGED; PORTUGAL; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0036396013     PISSN: 02511649     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. National Comprehensive Cancer Network: NCCN adult brain tumor practice guidelines. Oncology, 11, 237, 1997.
2. Pech I.V., Petersen K., Cairncross J.G. Chemotherapy for brain tumors. Oncology, 12, 537, 1998.
3. Yung W.K., Albright R.E., Olson J., et al. A phase II study of temozolomide vs procarbazine in patients with glioblastoma multiforme at first relapse. Br. J. Cancer, 83, 588, 2000.
4. 6-alkylguanine-DNA alkyltransferase levels: Studies with blasts of leukaemic patients. Ann. Oncol., 6, 389, 1995.
5. Stevens M.F.G., Hickmann J.A., Langdomn S.P., et al. Antitumor activity and pharmacokfnetfcs in mice of 8-Carbamoyl-3-metylimidazo[5,1-dl]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M&B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res., 47, 5846, 1987.
6. Clark A.S., Deans B., Stevens M.F.G., et al. Antitumor imidazotetrazines. 32. Synthesis of novel imidazotetrazinones and related bicyclic heterocycles to probe the mode of action of the antitumor drug temozolamide. J. Med. Chem., 38, 1493, 1995.
7. Newlands E.S, Blackledge G.R.P., Slack J.A., et al. Phase I trial of temozolomide (CCRG 81045:M&B 39831: NSC 362856). Br. J. Cancer, 65, 287, 1992
8. Brada M., Houng-Xuan K., Rampling R., et al. Multicenter phase II trial of temozolomide in patients with glioblastoma at first relapse. Ann. Oncol., 12, 259, 2001,
9. Yuang W.K.A, Temozolomide in malignant gliomas. Semin. Oncol., 27, 27, 2000.
10. Newlands E.S., Stevens M,F., Wedge S.R., Weelhouse R.T., Brock C. Temozolamide: A review of its discovery chemical properties, pre-clinical development and clinical trials. Cancer Treat Res., 23, 35, 1997.
11. Prados M.D., Levin V. Biology and treatment of malignant glioma. Semin. Oncol., 27, 1, 2000.